Patent Oppositions in immune drugs industry

Explore the competitive field of immune drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in immune drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the immune drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the immune drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Binding Molecules For Bcma And Cd3AMGENAug 26, 2026REGENERON PHARMACEUTICALS
Method And Compositions For Cellular ImmunotherapyFRED HUTCHINSON CANCER CENTERAug 26, 2026EIP
Crystal Forms Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-CarboxamideBRISTOL MYERS SQUIBBAug 11, 2026HAMPTON KNOWLES
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENE SWITZERLANDAug 5, 2026HAMPTON KNOWLES
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENEAug 4, 2026DEVA HOLDING
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENEAug 3, 2026SANDOZ
A1At For Reducing Risk Of Onset Of Acute Graft Versus Host Disease After Hematopoeitic Cell TransplantationCSL BEHRINGJul 28, 2026OCTAPHARMA
Biopharmaceutical CompositionsGLAXOSMITHKLINEJul 15, 2026HAMPTON KNOWLES
Method For Producing Cd8Alpha+Beta+Cytotoxic T CellsKYOTO UNIVERSITYJul 6, 2026MARGARET DIXON
Orodispersible Powder Composition Comprising An Antihistamine CompoundBIOPHARMA SYNERGIESJul 6, 2026PHARMA PATENTS

To stay ahead in the competitive immune drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the immune drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Oct 12, 2022S1P Receptor Modulators For Treating Multiple SclerosisNOVARTIS26
Nov 2, 2016Multiple-Variable Dose Regimen For Treating Tnfalpha-Related DisordersABBVIE BIOTECHNOLOGY11
Jan 18, 2017Methods Of Administering Anti-Tnfalpha AntibodiesABBVIE BIOTECHNOLOGY11
Dec 13, 2023Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARE9
Sep 11, 2019Binding Molecules For Bcma And Cd3AMGEN8
Jul 3, 2019Pharmaceutical Compositions Comprising An S1P ModulatorNOVARTIS8
Aug 21, 2019Binding Molecules For Bcma And Cd3AMGEN7
Mar 3, 2021Tofacitinib Oral Sustained Release Dosage FormsPFIZER7
Jul 27, 2022Use Of Dpp Iv InhibitorsBOEHRINGER INGELHEIM PHARMA GMBH & CO. KG6
Sep 2, 2020Process Of Modulating Man5 And/Or Afucosylation Content Of Glycoprotein CompositionDR REDDYS LABORATORIES6